Check for updates

#### **OPEN ACCESS**

EDITED BY Xiaojun Yu, Northwestern Polytechnical University, China

REVIEWED BY Songtao Yuan, Nanjing Medical University, China Yonathan Garfias, National Autonomous University of Mexico, Mexico

\*CORRESPONDENCE Xi Shen ⊠ carl\_shen2005@126.com

RECEIVED 07 September 2023 ACCEPTED 30 October 2023 PUBLISHED 14 November 2023

#### CITATION

Yao H, Yang Z, Cheng Y and Shen X (2023) Macular changes following cataract surgery in eyes with early diabetic retinopathy: an OCT and OCT angiography study. *Front. Med.* 10:1290599. doi: 10.3389/fmed.2023.1290599

#### COPYRIGHT

© 2023 Yao, Yang, Cheng and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Macular changes following cataract surgery in eyes with early diabetic retinopathy: an OCT and OCT angiography study

Huiping Yao, Zijian Yang, Yu Cheng and Xi Shen\*

Department of Ophthalmology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

**Background:** To evaluate changes in macular status and choroidal thickness (CT) following phacoemulsification in patients with mild to moderate nonproliferative diabetic retinopathy (NPDR) using optical coherence tomography.

**Methods:** In this prospective study, all of the patients underwent uncomplicated phacoemulsification. Retinal superficial capillary plexus vascular density (SCP-VD), macular thickness (MT), and CT were measured pre- and postoperatively.

**Results:** Twenty-two eyes of 22 cataract patients with mild to moderate NPDR without diabetic macular edema (DME) and 22 controls were enrolled. BCVA increased in two groups at 3 months postoperatively. At 1 and 3 months postoperatively, SCP-VD in the diabetic retinopathy (DR) group significantly increased; changes in SCP-VD in parafovea were significantly greater in the DR group than in the control group. MT and CT in the DR group significantly increased at all visits postoperatively in the fovea and perifovea. Changes in parafoveal MT were significantly greater in the DR group than in the control group at all visits postoperatively. Changes in CT and MT in the fovea were significantly greater in patients with DR than in the controls 1 and 3 months postoperatively.

**Conclusion:** Uncomplicated phacoemulsification resulted in greater increases in SCP-VD, MT and CT in patients with early DR without preoperative DME than in controls.

#### KEYWORDS

macular thickness, vascular density, choroidal thickness, optical coherence tomography, diabetic retinopathy, diabetic macular edema, optical coherence tomography angiography

# Introduction

Cataract is a leading cause of blindness worldwide (1), and diabetes mellitus (DM) is one of the most common diseases and its prevalence is increasing (2, 3). People with DM are five times more likely to develop cataracts than those without DM (4, 5). Phacoemulsification is the most common, effective, and safe procedures for the treatment of cataract. However, it was reported that cataract surgery was a risk factor for postoperative macular edema and secondary progression in diabetic patients (6). Macular edema and DR progression are the major reasons for poor visual prognosis after cataract surgery in diabetic patients with or without DR (7). While, it has also been suggested that these complications may not be a direct effect of surgery but rather a natural course of disease progression (8–10); therefore, it is clinically meaningful to determine the possible impact of cataract surgery on the occurrence of diabetic macular edema (DME) and/or the progression of DR. This may be related to the timing of cataract surgery as well as the treatment strategy for postoperative ME.

Fluorescent angiography (FA) and indocyanine green angiography (ICGA) are sensitive methods of detecting changes in the retinal and choroidal vasculature. FA is highly sensitive to retinal microvascular fluid leakage (11). However, there are many limitations to the clinical application of FA and ICGA owing to their invasive nature, the risk of allergic reactions, and the inability to achieve a good quantification of measurement. Optical coherence tomography (OCT) is thought to be more sensitive in detecting the presence of ME and is widely used to provide an objective and quantitative assessment of ME (12), providing more detailed images of the retinal and choroidal anatomy. Furthermore, optical coherence tomography angiography (OCTA) can help detect microvascular changes and assess retinal perfusion (13).

The aim of this study was to explore the influence of cataract surgery on macular microvasculature and macular and choroidal thicknesses in patients with mild/moderate DR through follow-up of changes in macular vascular density (VD), macular thickness (MT), and choroidal thickness (CT) using OCT and OCTA to evaluate the influence of phacoemulsification on retinal and choroidal microcirculation and structure.

## Methods

#### Study subjects

This prospective observational case–control study included 22 eyes of 22 patients with cataract, who were clinically diagnosed with mild to moderate nonproliferative diabetic retinopathy (NPDR) without DME, and 22 age-matched non-diabetic patients with cataract. All patients underwent complete ophthalmologic examinations, including slit-lamp examination, best-corrected visual acuity (BCVA), dilated fundal examinations, intraocular pressure (IOP), and axial length (AL). Classification and diagnosis of DR and DME were evaluated according to the international clinical disease DR severity scale (14). If a patient underwent surgery on both eyes, the eye that underwent surgery first was included in this study. This study was approved by the Ethical Review Committee of Ruijin Hospital and adhered to the provisions of the Declaration of Helsinki. The consent forms were signed by all patients.

All patients were recruited consecutively from the Ophthalmology Department of Ruijin Hospital between October 2020 and October 2022. The inclusion criteria were: age  $\geq$  40 years, spherical diopter <-6 D, AL < 26 mm, no history of intraocular surgery or ocular trauma, no history of DME and DR treatment, and no history of glaucoma, uveitis, or other retinal diseases, such as vitreoretinal interface disorders, retinal vein occlusion, retinal artery occlusion, etc.

#### Optical coherence tomography measurement

Swept source (SS)-OCT (Triton DRI-OCT, Topcon, Inc., Tokyo, Japan) was used to obtain OCT B-scan and angiography images.

Angiography scans  $(3 \times 3 \text{ mm})$  centered on the fovea and 12 radial scans through the center of the fovea were performed to obtain macular OCTA and B scan images. Images with a signal strength index >40 were saved for further analysis.

Superficial capillary plexus vascular density (SCP-VD), MT, and CT values were automatically provided by the built-in software of the SS-OCT device (Topcon FastMap, version 10.13.003.06). The macula was divided into three subfields according to the standard Early Treatment Diabetic Retinopathy Study (ETDRS) grid, as previously reported (15): foveal MT/VD were defined as values in the center circle (1.0 mm); parafoveal MT/CT/VD were defined as the arithmetic average values in the annular subfield with 1.0 mm inside and 3.0 mm outside diameter; and perifoveal MT/CT were defined as the arithmetic average values in the annular subfield with 3.0 mm inside and 6.0 mm outside diameter.

#### Surgery

One experienced surgeon performed all phacoemulsification procedures using the Infinity Vision System (Alcon Laboratories, Inc.). No surgery-related complications occurred, and intraocular lens was implanted into the capsular bag during surgery on each patient. The cumulative dissipated energy (CDE) data were collected. Tobramycin and dexamethasone eye drops 4 times per day were administered to all patients for 1 week after surgery, followed by 1.0% prednisolone acetate and 0.5% levofloxacin eye drops 3 times per day for 3 weeks.

#### Statistical analysis

Data were analyzed using GraphPad Prism 7.0 (GraphPad Software, CA) and expressed in the form of mean ± standard deviation (SD). The normal distribution of continuous variables was tested using D'Agostino & Pearson normality test. The differences between two groups were compared using independent t test. MT, CT, and SCP-VD at the four visits were compared using the repeated measures analysis of variance (ANOVA) with Bonferroni correction. Categorical variables were analyzed using Fisher's exact test. In addition, the repeated measures analysis of variance for the four visits with the inclusion of the CDE covariant (ANCOVA) was performed with SPSS software version 21.0 (SPSS, Inc., IL, Chicago, United States) to assess the effect of CDE on variations in OCTA parameter. p < 0.05 was considered statistically significant.

#### Results

#### Demographic and clinical characteristics

A total of 44 eyes of 44 participants were enrolled in the study; the DR group included 22 patients with mild to moderate NPDR (13 males and 9 females) and the control group included 22 nondiabetic patients (12 males and 10 females). There were no significant differences in age, sex, BCVA, IOP, CDE or AL between the two groups at baseline. The DR group included 3 patients with mild NPDR and 19 with moderate NPDR. BCVA at 3 months postoperatively

#### TABLE 1 Demographic and clinical characteristics.

|                            |             | Controls ( <i>n</i> = 22) | NPDR ( <i>n</i> = 22) | <i>p</i> -value |
|----------------------------|-------------|---------------------------|-----------------------|-----------------|
| Age, years (mean $\pm$ SD) |             | 65.9 ± 1.43               | 65.1 ± 1.68           | 0.727           |
| Gender (n)                 | Female      | 9                         | 10                    | . 0.000         |
|                            | Male        | 13                        | 12                    | >0.999          |
| BCVA, log MAR (mean ± SD)  | Baseline    | $0.75 \pm 0.19$           | 0.77 ± 0.21           | 0.710           |
|                            | 3 Mo postop | 0.07 ± 0.13               | 0.09 ± 0.1            | 0.615           |
|                            | Baseline    | 16.3 ± 2.31               | 16.1 ± 2.7            | 0.776           |
| IOP, mmHg                  | 1 Wk Postop | $12.4 \pm 3.46$           | 12.9 ± 2.6            | 0.59            |
| (mean±SD)                  | 1 Mo Postop | 13.8 ± 1.92               | 13.4 ± 2.05           | 0.522           |
|                            | 3 Mo Postop | $14.2 \pm 2.05$           | 14.1 ± 1.86           | 0.945           |
| Axial length, mm(mean±SD)  |             | $23.25 \pm 0.94$          | 23.31 ± 0.85          | 0.824           |
| CDE(mean ± SD)             |             | 6.61 ± 4.9                | 5.86 ± 3.1            | 0.546           |

NPDR, nonproliferative diabetic retinopathy; BCVA, best-corrected visual acuity; IOP, intraocular pressure; Wk, week; Postop, postoperatively; Mo, month; CDE, cumulative dissipated energy; SD, standard deviation.

TABLE 2 Superficial capillary plexus vascular density of the two groups at four visits (mean ± SD).

|                      | Baseline  |                  | Postop           |                |                  |         |                  |                |         |  |
|----------------------|-----------|------------------|------------------|----------------|------------------|---------|------------------|----------------|---------|--|
|                      |           | Daseune          | 1 Wk Postop      |                | 1 Mo Postop      |         | 3 Mo Postop      |                | p value |  |
|                      |           | VD               | VD               | <i>p</i> value | VD               | p value | VD               | <i>p</i> value |         |  |
| DR group             | Fovea     | $18.65\pm2.05$   | $18.23 \pm 1.72$ | 0.54           | $18.77 \pm 1.64$ | >0.999  | $18.48 \pm 1.78$ | >0.999         | 0.216   |  |
| (%)                  | Parafovea | $46.63 \pm 1.74$ | $47.18 \pm 1.35$ | 0.339          | 49.11 ± 1.69     | < 0.001 | $48.67 \pm 1.38$ | < 0.001        | < 0.001 |  |
| Control<br>group (%) | Fovea     | $19.2\pm2.6$     | $18.6\pm2.9$     | 0.478          | $19.38\pm3.01$   | >0.999  | 19.29 ± 2.9      | >0.999         | 0.213   |  |
|                      | Parafovea | 48.28 ± 2        | $48.58 \pm 1.86$ | >0.999         | $49.44 \pm 1.69$ | 0.122   | $49.05 \pm 1.45$ | 0.369          | 0.027   |  |

Wk, week; Postop, postoperatively; Mo, month; DR, diabetic retinopathy; VD, vascular density.

increased in DR and control groups (all p < 0.001). There was no significant difference in BCVA between the two groups at 3 months postoperatively (p = 0.615). In the control group, the IOP at 1 week, 1 month, and 3 months postoperatively was lower than at baseline (p < 0.001, p < 0.001, and p = 0.003, respectively), and in the DR group, the IOP at 1 week, 1 month, and 3 months postoperatively was also lower than at baseline (p < 0.001, p < 0.001, p < 0.001, and p = 0.003, respectively) (Table 1). One patient progressed from mild NPDR to moderate NPDR, while the other patients showed no progression in the stage of DR and no occurrence of DME at the last visit.

## Superficial capillary plexus vascular density

The microvasculature parameters obtained using OCTA at all visits are presented in Table 2. At baseline, there was no significant difference in foveal SCP-VD between the DR group and the control group (p=0.446); however, parafoveal SCP-VD in the DR group was lower than that in the control group (p=0.005).

In the DR group, there was no significant difference between postoperative foveal SCP-VD and baseline foveal SCP-VD at 1 week, 1 month, 3 months postoperatively; parafoveal SCP-VD at 1 week after surgery was not significantly different from baseline; parafoveal SCP-VD increased significantly at 1 and 3 months after surgery compared with baseline (Table 2). In the control group, SCP-VD after surgery was not significantly different from baseline at all visits postoperatively in fovea and parafovea (Table 2). In DR group, there existed significant difference in parafoveal SCP-VD between 1 week and 1 months postoperatively (p < 0.001), and the same was true between 1 week and 3 months postoperatively (p < 0.001); other than that, there were no significant differences in SCP-VD between any two time points postoperatively in both fovea and parafovea (all p > 0.05). In the control group, there were no significant differences in SCP-VD between any two time points postoperatively in both fovea and parafovea (all p > 0.05).

Changes in SCP-VD in the DR group were significantly greater than those in the control groups 1 and 3 months postoperatively in the parafovea. Changes in SCP-VD in the DR group were not significantly different from those of the control group in the fovea at 1 week, 1 month and 3 months postoperatively (Table 3).

ANCOVA test did not show relationships between CDE and variations in SCP-VD in both DR and control groups. After adjusting for CDE, parafoveal SCP-VD increased significantly at 1 and 3 months after surgery compared with baseline in the DR group (Supplementary Tables S1, S2).

## Macular thickness

At baseline, there was no significant difference between the DR and control group in the foveal, parafoveal, and perifoveal MT (p = 0.637, 0.927, and 0.773, respectively).

The MT of the DR group significantly increased at 1 week, 1 month, and 3 months postoperatively compared with baseline in all

|     |           | 1 Wk Postop      |               |         | 1               | Mo Postop       |         | 3 Mo Postop     |                  |         |
|-----|-----------|------------------|---------------|---------|-----------------|-----------------|---------|-----------------|------------------|---------|
|     |           | Control          | DR            | p value | Control         | DR              | p value | Control         | DR               | p value |
| VD  | Fovea     | $-0.59 \pm 1.51$ | $-0.42\pm1.1$ | 0.671   | $0.18 \pm 1.79$ | $0.11 \pm 1.67$ | 0.895   | $0.09\pm2.3$    | $-0.17 \pm 1.68$ | 0.673   |
| (%) | Parafovea | $0.3 \pm 1.45$   | 0.56 ± 1.3    | 0.529   | $1.16\pm2.17$   | $2.49 \pm 1.96$ | 0.038   | $0.77 \pm 1.82$ | $2.05 \pm 1.35$  | 0.011   |

TABLE 3 Changes in superficial capillary plexus vascular density after cataract surgery (mean ± SD).

Wk, week; Postop, postoperatively; Mo, month; DR, diabetic retinopathy; VD, vascular density.

#### TABLE 4 The macular thickness of the two groups at four visits (mean $\pm$ SD).

|                 |           | Baseline          | Postop           |         |                 |         |                   |                |                |  |  |
|-----------------|-----------|-------------------|------------------|---------|-----------------|---------|-------------------|----------------|----------------|--|--|
|                 |           | Daseune           | 1 Wk Postop      |         | 1 Mo Postop     |         | 3 Mo Postop       |                | <i>p</i> value |  |  |
|                 |           | MT                | MT               | p value | MT              | p value | MT                | <i>p</i> value |                |  |  |
|                 | Fovea     | 219.3 ± 19.98     | 228.8 ± 21.38    | 0.004   | $244\pm25.42$   | < 0.001 | $236.5 \pm 21.53$ | < 0.001        | <0.001         |  |  |
| Control<br>(µm) | Parafovea | $292.2\pm20.28$   | 299.3 ± 18.54    | 0.014   | 311 ± 15.14     | < 0.001 | $303.9 \pm 18.51$ | 0.002          | <0.001         |  |  |
| (µ111)          | Perifovea | $264.4 \pm 16.03$ | 271.2 ± 16.83    | 0.067   | $281.5\pm23.78$ | < 0.001 | $271.2\pm17.45$   | < 0.001        | <0.001         |  |  |
|                 | Fovea     | 222.3 ± 21.85     | 235.2 ± 20.21    | < 0.001 | 262.1 ± 31.15   | < 0.001 | 257.1 ± 28.92     | < 0.001        | <0.001         |  |  |
| DR (µm)         | Parafovea | $291.5\pm25.07$   | $306.9 \pm 18.8$ | < 0.001 | 318.8 ± 21.12   | < 0.001 | 314.1 ± 19.2      | 0.001          | <0.001         |  |  |
|                 | Perifovea | 266 ± 18.97       | 277.9 ± 18.11    | 0.022   | $290\pm20.04$   | <0.001  | $286.3 \pm 17.87$ | <0.001         | <0.001         |  |  |

Wk, week; Postop, postoperatively; Mo, month; DR, diabetic retinopathy; MT, macular thickness.

TABLE 5 Changes of macular thickness after cataract surgery (mean ± SD).

|            |           |              | 1 Wk Pc          | ostop      |                   | 1 Mo Po           | stop       | 3 Mo Postop       |                   |            |
|------------|-----------|--------------|------------------|------------|-------------------|-------------------|------------|-------------------|-------------------|------------|
|            |           | Control      | DR               | p<br>value | Control           | DR                | p<br>value | Control           | DR                | p<br>value |
|            | Fovea     | 9.5 ± 11.5   | $13.0 \pm 11.1$  | 0.323      | $24.68\pm20.01$   | 39.86 ± 19.34     | 0.014      | 17.23 ± 13.15,    | 34.86 ± 17.68     | 0.001      |
| MT<br>(μm) | Parafovea | 7.16 ± 9.69  | 15.38 ± 13.91    | 0.028      | 18.87 ± 12.35     | $27.24 \pm 12.64$ | 0.032      | $11.69 \pm 12.87$ | 22.55 ± 13.95     | 0.01       |
| (µ111)     | Perifovea | 6.75 ± 11.38 | $11.9 \pm 17.02$ | 0.245      | $17.11 \pm 17.32$ | $24.06 \pm 17.32$ | 0.177      | $6.75 \pm 6.21$   | $20.38 \pm 16.81$ | 0.001      |

Wk, week; Postop, postoperatively; Mo, month; DR, diabetic retinopathy; MT, macular thickness.

subfields; in the control group, the MT significantly increased at 1 week, 1 month, and 3 months postoperatively in fovea and parafovea, and significantly increased at 1 and 3 months postoperatively compared with baseline in perifovea (Table 4).

In DR group, there existed significant difference between MT at 1 week and 1 month postoperatively in the fovea, parafovea, and perifovea (p < 0.001, p < 0.001, and p < 0.001, respectively); the same was true between MT at 1 and 3 months postoperatively in the fovea, parafovea (p = 0.02 and 0.02, respectively) and between MT at 1 week and 3 months postoperatively in the fovea, parafovea, and perifovea (p = 0.001, p = 0.008, and p < 0.001, respectively). In control group, there existed significant difference between MT at 1 week and 1 month postoperatively in the fovea, parafovea, and perifovea (p < 0.001, p < 0.001, and p = 0.007, respectively); the same was true between MT at 1 and 3 months postoperatively in the parafovea, perifovea (p = 0.021 and 0.032, respectively).

Changes in MT in the DR group were significantly greater than those in the control group at 1 and 3 months postoperatively in the fovea and parafovea, and the same was true for MT in the parafovea at 1 week postoperatively and in the perifovea at 3 months postoperatively (Table 5).

The distribution of foveal MT of the control and DR groups is shown in Table 6. The proportion of foveal MT >250 $\mu$ m reached its maximum, up to 68.2%, at 1 month postoperatively and was 54.5% at 3 months postoperatively in the DR group, while in the control group it was highest at 1 month (40.9%). There was no significant difference in the distribution of foveal MT between the two groups (Table 6). No patient was found to develop to pseudophakic cystoid macular edema (PCME) during the follow-up period (Figure 1).

## Choroidal thickness


At baseline, there were no significant difference between the DR and control groups in foveal, parafoveal and perifoveal CT (p = 0.376, 0.203, and 0.107, respectively).

The CT of the DR group increased significantly at 1 week, 1 month and 3 months postoperatively in the fovea and perifovea and 1 month and 3 months postoperatively in the parafovea compared with baseline (Table 7). In the DR group, there existed significant difference in CT between 1 week and 1 month postoperatively in the fovea (p = 0.019); other than that, there were no significant differences in CT between any two time points postoperatively in both fovea and parafovea (all p > 0.05). In the control group, there were no significant differences in CT between any two time points in all subfields (all p > 0.05).

Changes of CT in the DR group were significantly greater than those of the control group at 1 and 3 months postoperatively in the fovea, and at 3 months postoperatively in the parafovea (Table 8). TABLE 6 Distribution of foveal macular thickness of the two groups at four visits (mean  $\pm$  SD).

| Foveal MT<br>(µm) | Baseline   |          | 1 Wk Postop |           | 1 Mo I               | Postop     | 3 Mo Postop |            |
|-------------------|------------|----------|-------------|-----------|----------------------|------------|-------------|------------|
|                   | ≤250       | >250     | ≤250        | >250      | ≤250                 | >250       | ≤250        | >250       |
| DR( <i>n</i> , %) | 20 (90.9%) | 2 (9.1%) | 16 (72.7%)  | 6 (27.3%) | 7 (31.8%)            | 15 (68.2%) | 10 (45.5%)  | 12 (54.5%) |
| Control(n, %)     | 22 (100%)  | 0        | 19 (86.4%)  | 3 (13.6%) | 13 (59.1%) 9 (40.9%) |            | 16 (72.7%)  | 6 (27.3%)  |
| <i>p</i> -value   | 0.488      |          | 0.457       |           | 0.13                 |            | 0.124       |            |

Wk, week; Postop, postoperatively; Mo, month; MT, macular thickness.



#### FIGURE 1

This figure shows the changes in macular thickness (MT) preoperatively (A) and 1 week (B), 1 month (C), and 3 months (D) postoperatively in a patient with moderate DR. MT in the central 1,000 µm increased after surgery, increasing to 251 µm, and absent of pseudophakic cystoid macular oedema (PCME).

| TABLE 7 | The choroidal thickness | of the two groups | at four visits (mean $\pm$ SD). |
|---------|-------------------------|-------------------|---------------------------------|
|---------|-------------------------|-------------------|---------------------------------|

|         |           | Baseline          | Postop            |                 |                   |                 |                   |                 |                 |  |
|---------|-----------|-------------------|-------------------|-----------------|-------------------|-----------------|-------------------|-----------------|-----------------|--|
|         |           | Daseune           | 1 Wk Postop       |                 | 1 Mo Postop       |                 | 3 Mo Postop       |                 | <i>p</i> -value |  |
|         |           | СТ                | СТ                | <i>p</i> -value | СТ                | <i>p</i> -value | СТ                | <i>p</i> -value |                 |  |
|         | Fovea     | 222.6 ± 104.5     | 226.8 ± 107.8     | 0.57            | $228.8 \pm 110.1$ | >0.999          | $229.5 \pm 112.4$ | 0.273           | 0.346           |  |
| Control | Parafovea | 220 ± 101.2       | 224.4 ± 105.9     | 0.667           | 228.6 ± 106.9     | 0.115           | $226.5\pm105.4$   | 0.21            | 0.022           |  |
| (µm)    | Perifovea | 193.1 ± 84.98     | 198.3 ± 87.8      | 0.694           | $202.7\pm87.35$   | 0.066           | $201.8\pm89.17$   | 0.131           | 0.015           |  |
|         | Fovea     | 199.6 ± 59.2      | $211.4 \pm 66.57$ | 0.041           | $219.5\pm 64.53$  | < 0.001         | $216.3\pm62.61$   | < 0.001         | < 0.001         |  |
| DR (µm) | Parafovea | 188.1 ± 56        | $199.2 \pm 62.87$ | 0.064           | $204.3\pm57.48$   | < 0.001         | $203.4\pm57.48$   | 0.001           | < 0.001         |  |
|         | Perifovea | $158.8 \pm 48.44$ | $168.7\pm53.78$   | 0.039           | $174.7\pm49.07$   | < 0.001         | $172.4\pm48.2$    | 0.001           | < 0.001         |  |

Wk, week; Postop, postoperatively; Mo, month.

|            |           | 1 Wk Postop      |                   |            | 1            | Mo Postop         |            | 3 Mo Postop  |                   |                   |
|------------|-----------|------------------|-------------------|------------|--------------|-------------------|------------|--------------|-------------------|-------------------|
|            |           | Control          | DR                | p<br>value | Control      | DR                | p<br>value | Control      | DR                | <i>p</i><br>value |
|            | Fovea     | $4.25 \pm 11.4$  | $11.77 \pm 18.42$ | 0.111      | 6.21 ± 28.81 | 19.83 ± 12.06     | 0.035      | 6.93 ± 15.29 | 16.63 ± 13.38     | 0.031             |
| CT<br>(μm) | Parafovea | $4.43 \pm 12.5$  | 11.13 ± 18.62     | 0.169      | 8.64 ± 15.95 | $16.24 \pm 16.37$ | 0.126      | 6.51 ± 13.54 | $15.34 \pm 14.71$ | 0.045             |
| (µ11)      | Perifovea | $5.17 \pm 14.78$ | 9.89 ± 15.32      | 0.305      | 9.56 ± 16.1  | 15.94 ± 10        | 0.121      | 8.67 ± 16.42 | 13.6 ± 14.23      | 0.293             |

TABLE 8 Changes in choroidal thickness after cataract surgery (mean ± SD).

Wk, week; Postop, postoperatively; Mo, month; DR, diabetic retinopathy; CT, choroidal thickness.

# Discussion

Breakdown of the blood-retina barrier (BRB) can lead to the development of DR and ME (16). On the other hand, choroid is the only source of metabolic exchange for the avascular fovea (17). Postoperative inflammation may aggravate choroidal microvascular lesions, in addition to the retinal microcirculation (18). It is of great significance to clarify retinal and choroidal changes and the relationship with the occurrence of ME and deterioration of DR after cataract surgery in patients with DR, especially in early DR without DME, in which the occurrence of ME and the progression of retinopathy are crucial to postoperative visual prognosis.

Here, we report a significant increase in MT within 3 months after cataract surgery in a specific population with mild to moderate DR. George et al. observed hyperfluorescence of the macula and optic disc postoperatively on fluorescein angiography in the surgical eyes, which was greater than that in the nonsurgical eyes (19). Moreover, increased macular thickness has previously been reported in surgical diabetic eyes (18, 20), which is similar to the results of our research, although the population studied was not entirely consistent. We also observed a significant increase in CT after surgery in the DR group. This finding is consistent with the results of previous studies (15, 21-23). In addition, MT in the parafovea, and perifovea increased significantly in the control group at 1 week, 1 month, and 3 months postoperatively; while CT in the parafovea and perifovea slightly increased, though which was not significantly thicker than baseline in the control group at 1 month postoperatively. This indicates that surgical trauma itself induces a rapid increase in macular and choroidal thicknesses. To the best of our knowledge, this is the first observational follow-up study about macular microvasculature changes after phacoemulsification in this specific population of patients with mild to moderate DR using the OCTA-based VD calculation and analysis. SCP-VD in the parafoveal macula increased significantly at 1 and 3 months postoperatively compared with baseline in patients with DR in this study. This is consistent with a previous study that reported that vascular densities increased in both the SCP and deep capillary plexus (DCP) after cataract surgery (24-26). This may be due to postoperative inflammation. Inflammation is suspected to be involved in cataract surgery-mediated retinal complications. Cataract surgery induces markedly upregulated expression of IL-1 and CCL2 genes in the retina and choroid (27). In animal studies, breakdown of the inner BRB was observed after lens aspiration (28). And it was reported that decreased IOP resulted in an increase in leukocyte flow speed and choroidal thickness in the macula (22, 29). IOL decreased significantly after surgery in our study, which may be another cause of the increased VD and CT postoperatively.

What is more noteworthy is that, in our study, changes in foveal/ parafoveal MT and foveal CT in patients with DR were significantly greater than those in controls at 1 and 3 months postoperatively; changes in SCP-VD in patients with DR were significantly greater than those in the control group in the parafovea at 1 and 3 months postoperatively. Presumably, it was suggested that cataract surgery might increase the risk of macular edema in patients with mild/ moderate DR compared with patients without diabetes, which may be due to defects in blood-retinal barrier function in those patients with more advanced vascular changes caused by microvascular destruction in DR than in normal individuals. This finding is consistent with those of other studies. It has been reported that the retinal thickness of diabetic patients has a significantly increasing trend compared with that in non-diabetic patients (30). The presence of diabetes was a risk factor of pseudophakic macular edema (PME) and the risk increased approximately linearly with the severity of retinopathy (31). However, previous studies found no significant difference in the magnitude of changes after cataract surgery between diabetic and non-diabetic patients (32). This is inconsistent with our results and may be due to the inclusion of different patient population, and the patients enrolled in their study had less severe DR.

As is well-known, inflammation plays a role in retinal microvasculature damage and exists at different stages of DR. It plays a crucial role in the pathogenesis of DR by increasing retinal vascular permeability and promoting neovascularization, which leads to the occurrence and development of DME and DR (33-35). Diabetic patients exhibit an overall higher level of inflammatory activity than non-diabetic patients, according to previous clinical and laboratory studies (36-38). The expression of vascular endothelial growth factor (VEGF), which may be involved in increased vascular permeability and angiogenesis, is upregulated in the diabetic retina and choroid (39). And the levels of VEGF and IL-6 in aqueous humor are significantly correlated with macular edema severity in diabetic patients (40). The significantly greater changes in MT, foveal CT, and parafoveal VD observed at 1 and 3 months postoperatively in the DR group than in the control group may be due to the inflammation present in DR. Preexisting inflammatory activity caused by DR, as well as the surgery-induced inflammatory process, might be the cause of increased VD, MT, and CT in patients with mild/moderate NPDR in the present study.

In addition to postoperative inflammation, it was reported that anterior–posterior (AP) traction induced by the surgery procedure might also be a risk factor for macular edema after cataract surgery, and AP traction could disrupt the macular microcirculation, including blood–retinal barrier disfunction and increasing vascular permeability (41). In this study, MT and SCP-VD peaked 1 month postoperatively. Compared to macular thickening caused solely by mechanical traction

itself during the surgery, the disrupted macular microcirculation induced by surgery is more likely to be the direct cause of macular thickening. Furthermore, several studies have investigated the relationship between CDE and changes in retinal microcirculation after surgery. In some studies, patients with higher CDE values were reported to have a more significant reduction in VD after surgery (42, 43). In another study, it was found that changes in VD after surgery were not significantly correlated with CDE; therefore, they concluded that CDE had little effect on retinal microcirculation (32). This is consistent with our results. In the present study, there was no significant difference between the two groups, and ANCOVA test did not show relationships between CDE and variations in SCP-VD, which may imply that CDE had little effect on postoperative VD changes. There is some controversy among studies, and this may be due to the inclusion of different patient population and difference in levels of CDE between studies. Presumably, the CDE recorded in the present study was relatively small and insufficient to have a significant effect on OCT parameters. Randomized controlled trials with a large sample size should be needed in future.

In our study, MT, SCP-VD, and CT peaked 1 month after surgery. Previous reports have also shown that the incidence of ME peaks approximately 4–6 weeks after uneventful cataract surgery (44, 45). Temporally, the increases in CT, VD and MT seemed to coincide with the timing of the previously reported appearance of ME after surgery. Presumably, postoperative inflammation had the greatest impact on MT, SCP-VD, and CT at 1 month after surgery. From the point of view of time, it seems that choroidal and retinal microcirculation disorders might both be likely to be associated with the increase in MT postoperatively. Nevertheless, further research is required to determine whether the choroid is involved in the development of PME.

In this study, none of the patients developed to DME or PCME during the follow-up period. Foveal MT increased significantly after cataract surgery; foveal MT of more than 250 µm was as high as 68.2% at 1 month postoperatively. Central subfield thickness (CST), which is defined as average retinal thickness in the central 1,000 µm, corresponds to the foveal MT in this study, and 250 µm is usually the CST threshold value for diagnosing DME (46); however, no patients developed DME during the period of follow-up in our study. And in this study, BCVA of patients with DR was equivalent to that of nondiabetic individuals after surgery; therefore, increasing foveal MT could be considered a subclinical macular thickness thickening that did not affect visual acuity and was not a support of PCME, which is consistent with a previous study (10). In addition, DME and PCME after surgery were not be observed in this study, which might be due to the small size and short follow-up period. Moreover, it was reported that the risk of PME in patients with DR is high and increases with the severity of DR (31); preoperative noncenter-involved DME or a history of DME treatment may increase the risk of center-involved DME at 16 weeks after surgery (47). This study enrolled the patients with early DR and without a history of DME, which may be another reason for these observations.

Furthermore, at baseline, the parafoveal VD of DR patients was lower than that of the controls. It was previously reported that VD decreased in patients with DR without macular edema, and that VD parameters decreased with increasing DR severity (48). The foveal VD of patients with DR in our study was slightly lower than that of the controls, although the difference was not significant. This may be due to the small sample size or the fact that the population enrolled in our study included cataract patients with mild/moderate NPDR without preoperative DME, which does not reflect the full spectrum of patients with DR. However, there was no significant difference in MT between the DR and control groups at baseline. This may indicate that microvasculature changes occur before macular structural changes in patients with early DR.

This study had a few limitations. The sample size was relatively small, but the participants were homogeneous in terms of degree of retinopathy, ethnicity and sex, reducing some confounding effects. Moreover, the follow-up period was too short that we cannot observe the long-term effects on retina vessels and structural changes. Longterm follow-up is required to determine the duration of the increase in MT, CT, and VD after cataract surgery and its long-term relationship with the progression of DR severity and incidence of DME, which may be suggestive of a higher incidence of ME in this population. Future studies should enroll a larger sample of participants with longer follow-up periods.

# Conclusion

Uncomplicated phacoemulsification results in a greater increase in MT, SCP-VD, and CT in patients with mild/moderate NPDR without preoperative DME than in controls. This may be suggestive of a predisposition to the occurrence of macular edema in this population, which may be due to the preexisting inflammatory activity caused by DR as well as cataract surgery trauma. However, the shortterm postoperative visual prognosis of cataract patients with mild to moderate NPDR without preoperative DME is the same as that of healthy patients in this study.

## Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

## **Ethics statement**

The studies involving humans were approved by the Ethical Review Committee of Ruijin Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

# Author contributions

HY: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft. ZY: Data curation, Investigation, Writing – review & editing. YC: Methodology, Supervision, Validation, Writing – review & editing. XS: Conceptualization, Data curation, Investigation, Methodology, Supervision, Validation, Writing – review & editing.

# Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by Shanghai Municipal Health Commission, grant number 202140183.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## References

1. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. *Lancet Glob Health.* (2017) 5:e1221–34. doi: 10.1016/S2214-109X(17)30393-5

2. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. *N Engl J Med.* (2010) 362:1090–101. doi: 10.1056/NEJMoa0908292

3. Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. *Arch Ophthalmol.* (2008) 126:1740–7. doi: 10.1001/archopht.126.12.1740

4. Javadi MA, Zarei-Ghanavati S. Cataracts in diabetic patients: a review article. J Ophthalmic Vis Res. (2008) 3:52-65.

5. Pollreisz A, Schmidt-Erfurth U. Diabetic cataract-pathogenesis, epidemiology and treatment. J Ophthalmol. (2010) 2010:608751:1-8. doi: 10.1155/2010/608751

6. Menchini U, Cappelli S, Virgili G. Cataract surgery and diabetic retinopathy. Semin Ophthalmol. (2003) 18:103-8. doi: 10.1076/soph.18.3.103.29805

 Squirrell D, Bhola R, Bush J, Winder S, Talbot JF. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. Br J Ophthalmol. (2002) 86:565–71. doi: 10.1136/bjo.86.5.565

8. Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. *Arch Ophthalmol.* (2004) 122:330–5. doi: 10.1001/archopht.122.3.330

9. Browning DJ, McOwen MD, Bowen RM Jr, O'Marah TL. Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. *Ophthalmology*. (2004) 111:712–5. doi: 10.1016/j.ophtha.2003.06.028

10. Eriksson U, Alm A, Bjärnhall G, Granstam E, Matsson AW. Macular edema and visual outcome following cataract surgery in patients with diabetic retinopathy and controls. *Graefes Arch Clin Exp Ophthalmol.* (2011) 249:349–59. doi: 10.1007/s00417-010-1484-9

11. Hee MR, Puliafito CA, Wong C, Duker JS, Reichel E, Rutledge B, et al. Quantitative assessment of macular edema with optical coherence tomography. *Arch Ophthalmol.* (1995) 113:1019–29. doi: 10.1001/archopht.1995.01100080071031

12. Im JHB, Jin YP, Chow R, Yan P. Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: a systematic review and metaanalysis. *Surv Ophthalmol.* (2022) 67:1244–51. doi: 10.1016/j.survophthal.2022.01.009

13. Ghassemi F, Fadakar K, Berijani S, Babeli A, Gholizadeh A, Sabour S. Quantitative assessment of vascular density in diabetic retinopathy subtypes with optical coherence tomography angiography. *BMC Ophthalmol.* (2021) 21:82. doi: 10.1186/s12886-021-01831-8

14. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. *Ophthalmology*. (2003) 110:1677–82. doi: 10.1016/S0161-6420(03)00475-5

15. Yao H, Gao S, Liu X, Zhou Y, Cheng Y, Shen X. Choroidal structural changes assessed with swept-source optical coherence tomography after cataract surgery in eyes with diabetic retinopathy. *J Ophthalmol.* (2020) 2020:1–9. doi: 10.1155/2020/5839837

16. Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. *Eur J Ophthalmol.* (2011) 21:3–9. doi: 10.5301/EJO.2010.6049

17. Mrejen S, Spaide RF. Optical coherence tomography: imaging of the choroid and beyond. *Surv Ophthalmol.* (2013) 58:387–429. doi: 10.1016/j.survophthal.2012.12.001

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2023.1290599/ full#supplementary-material

18. Brito PN, Rosas VM, Coentrão LM, Carneiro ÂV, Rocha-Sousa A, Brandão E, et al. Evaluation of visual acuity, macular status, and subfoveal choroidal thickness changes after cataract surgery in eyes with diabetic retinopathy. *Retina*. (2015) 35:294–302. doi: 10.1097/IAE.00000000000298

19. Escaravage GK Jr, Cohen KL, Patel SB, Hartnett ME, Armstrong BD, Janowski CM. Quantification of macular and optic disc hyperfluorescence after phacoemulsification in diabetes mellitus. *J Cataract Refract Surg.* (2006) 32:803–11. doi: 10.1016/j. jcrs.2006.01.073

20. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. *Ophthalmology.* (2007) 114:881–9. doi: 10.1016/j.ophtha.2006.08.053

21. Aslan Bayhan S, Bayhan HA, Muhafiz E, Kırboğa K, Gürdal C. Evaluation of choroidal thickness changes after phacoemulsification surgery. *Clin Ophthalmol.* (2016) 10:961–7. doi: 10.2147/OPTH.S94096

22. Ohsugi H, Ikuno Y, Ohara Z, Imamura H, Nakakura S, Matsuba S, et al. Changes in choroidal thickness after cataract surgery. *J Cataract Refract Surg.* (2014) 40:184–91. doi: 10.1016/j.jcrs.2013.07.036

23. Yılmaz T, Karci AA, Yilmaz İ, Yılmaz A, Yıldırım Y, Sakalar YB. Long-term changes in subfoveal choroidal thickness after cataract surgery. *Med Sci Monit.* (2016) 22:1566–70. doi: 10.12659/MSM.898714

24. Zhao Z, Wen W, Jiang C, Lu Y. Changes in macular vasculature after uncomplicated phacoemulsification surgery: optical coherence tomography angiography study. *J Cataract Refract Surg.* (2018) 44:453–8. doi: 10.1016/j.jcrs.2018.02.014

25. Yu S, Frueh BE, Steinmair D, Ebneter A, Wolf S, Zinkernagel MS, et al. Cataract significantly influences quantitative measurements on swept-source optical coherence tomography angiography imaging. *PLoS One.* (2018) 13:e0204501. doi: 10.1371/journal. pone.0204501

26. Jia X, Wei Y, Song H. Optical coherence tomography angiography evaluation of the effects of phacoemulsification cataract surgery on macular hemodynamics in Chinese normal eyes. *Int Ophthalmol.* (2021) 41:4175–85. doi: 10.1007/s10792-021-01987-8

27. Xu H, Chen M, Forrester JV, Lois N. Cataract surgery induces retinal proinflammatory gene expression and protein secretion. *Invest Ophthalmol Vis Sci.* (2011) 52:249–55. doi: 10.1167/iovs.10-6001

28. Liu H, Demetriades AM, Xiao WH, Campochiaro PA, Vinores SA. Mouse model of post-surgical breakdown of the blood-retinal barrier. *Curr Eye Res.* (2004) 28:421–6. doi: 10.1080/02713680490503769

29. Grunwald JE, Sinclair SH, Riva CE. Autoregulation of the retinal circulation in response to decrease of intraocular pressure below normal. *Invest Ophthalmol Vis Sci.* (1982) 23:124–7.

30. Degenring RF, Vey S, Kamppeter B, Budde WM, Jonas JB, Sauder G. Effect of uncomplicated phacoemulsification on the central retina in diabetic and nondiabetic subjects. *Graefes Arch Clin Exp Ophthalmol.* (2007) 245:18–23. doi: 10.1007/s00417-006-0377-4

31. Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC. Risk factors and incidence of macular Edema after cataract surgery: a database study of 81984 eyes. *Ophthalmology*. (2016) 123:316–23. doi: 10.1016/j.ophtha.2015.10.001

32. Feng L, Azhati G, Li T, Liu F. Macular vascular density changes following cataract surgery in diabetic patients: an optical coherence tomography angiography study. *J Ophthalmol.* (2021) 2021:1–7. doi: 10.1155/2021/6641944

33. Kaštelan S, Tomić M, Gverović Antunica A, Salopek Rabatić J, Ljubić S. Inflammation and pharmacological treatment in diabetic retinopathy. *Mediat Inflamm.* (2013) 2013:213130:1–8. doi: 10.1155/2013/213130

34. Gouliopoulos NS, Kalogeropoulos C, Lavaris A, Rouvas A, Asproudis I, Garmpi A, et al. Association of serum inflammatory markers and diabetic retinopathy: a review of literature. *Eur Rev Med Pharmacol Sci.* (2018) 22:7113–28. doi: 10.26355/eurrev\_201811\_16243

35. Capitão M, Soares R. Angiogenesis and inflammation crosstalk in diabetic retinopathy. J Cell Biochem. (2016) 117:2443-53. doi: 10.1002/jcb.25575

36. Dong N, Xu B, Wang B, Chu L, Tang X. Aqueous cytokines as predictors of macular edema in patients with diabetes following uncomplicated phacoemulsification cataract surgery. *Biomed Res Int*. (2015) 2015:126984:1–8. doi: 10.1155/2015/126984

37. Hernández C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simó R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. *Diabet Med.* (2005) 22:719–22. doi: 10.1111/j.1464-5491.2005.01538.x

38. Dong N, Li X, Xiao L, Yu W, Wang B, Chu L. Upregulation of retinal neuronal MCP-1 in the rodent model of diabetic retinopathy and its function in vitro. *Invest Ophthalmol Vis Sci.* (2012) 53:7567–75. doi: 10.1167/iovs.12-9446

39. Lutty GA, McLeod DS, Merges C, Diggs A, Plouet J. Localization of vascular endothelial growth factor in human retina and choroid. *Arch Ophthalmol.* (1996) 114:971–7. doi: 10.1001/archopht.1996.01100140179011

40. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. *Am J Ophthalmol.* (2002) 133:70–7. doi: 10.1016/S0002-9394(01)01269-7

41. Copete S, Martí-Rodrigo P, Muñiz-Vidal R, Pastor-Idoate S, Rigo J, Figueroa MS, et al. Preoperative vitreoretinal interface abnormalities on spectral domain

optical coherence tomography as risk factor for PSEUDOPHAKIC cystoid macular EDEMA after phacoemulsification. *Retina*. (2019) 39:2225–32. doi: 10.1097/IAE.00000000002298

42. Wang Z, Wang E, Chen Y. Transient reduction in macular deep capillary density on optical coherence tomography angiography after phacoemulsification surgery in diabetic patients. *BMC Ophthalmol.* (2020) 20:335. doi: 10.1186/s12886-020-01605-8

43. Tan LZ, Tian F, Chen L, Sun LN, Gong X, Liang JL, et al. Changes in the peripapillary vasculature and macular thickness after cataract surgery using two phacoemulsification systems with optical coherence tomography angiography. *Int J Ophthalmol.* (2022) 15:932–9. doi: 10.18240/ijo.2022.06.10

44. Perente I, Utine CA, Ozturker C, Cakir M, Kaya V, Eren H, et al. Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography. *Curr Eye Res.* (2007) 32:241–7. doi: 10.1080/02713680601160610

45. Buyukyildiz HZ, Gulkilik G, Kumcuoglu YZ. Early serous macular detachment after phacoemulsification surgery. *J Cataract Refract Surg.* (2010) 36:1999–2002. doi: 10.1016/j.jcrs.2010.07.007

46. Wang YT, Tadarati M, Wolfson Y, Bressler SB, Bressler NM. Comparison of prevalence of diabetic macular Edema based on monocular fundus photography vs optical coherence tomography. *JAMA Ophthalmol.* (2016) 134:222–8. doi: 10.1001/jamaophthalmol.2015.5332

47. Arevalo JF. Diabetic macular edema: changing treatment paradigms. *Curr Opin Ophthalmol.* (2014) 25:502–7. doi: 10.1097/ICU.000000000000102

48. Samara WA, Shahlaee A, Adam MK, Khan MA, Chiang A, Maguire JI, et al. Quantification of diabetic macular ischemia using optical coherence tomography angiography and its relationship with visual acuity. *Ophthalmology*. (2017) 124:235–44. doi: 10.1016/j.ophtha.2016.10.008